Galmed Pharmaceuticals Ltd. (GLMD) Given a $14.00 Price Target at Maxim Group

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) has been given a $14.00 target price by Maxim Group in a research note issued on Thursday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Maxim Group’s price target suggests a potential upside of 52.17% from the stock’s current price.

GLMD has been the subject of a number of other reports. ValuEngine upgraded Galmed Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, June 17th. HC Wainwright boosted their price target on Galmed Pharmaceuticals from $12.00 to $18.00 and gave the company a “buy” rating in a report on Tuesday, August 8th. Finally, Zacks Investment Research upgraded Galmed Pharmaceuticals from a “hold” rating to a “buy” rating and set a $8.00 price target for the company in a report on Wednesday, August 2nd.

Shares of Galmed Pharmaceuticals (NASDAQ GLMD) traded up 4.66% during trading on Thursday, reaching $9.20. 58,840 shares of the company’s stock traded hands. The stock’s market capitalization is $112.41 million. The company has a 50 day moving average price of $8.24 and a 200 day moving average price of $6.41. Galmed Pharmaceuticals has a 1-year low of $2.78 and a 1-year high of $9.39.

Galmed Pharmaceuticals (NASDAQ:GLMD) last announced its earnings results on Monday, July 31st. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.33) by $0.11. Galmed Pharmaceuticals had a negative return on equity of 141.13% and a negative net margin of 1,443.98%. The company had revenue of $0.27 million for the quarter, compared to analyst estimates of $0.29 million. On average, equities analysts forecast that Galmed Pharmaceuticals will post ($0.94) EPS for the current fiscal year.

WARNING: This piece was first published by American Banking News and is the property of of American Banking News. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/10/05/galmed-pharmaceuticals-ltd-glmd-given-a-14-00-price-target-at-maxim-group.html.

An institutional investor recently bought a new position in Galmed Pharmaceuticals stock. KCG Holdings Inc. acquired a new position in shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 20,473 shares of the biopharmaceutical company’s stock, valued at approximately $100,000. KCG Holdings Inc. owned about 0.17% of Galmed Pharmaceuticals at the end of the most recent reporting period. 8.32% of the stock is currently owned by institutional investors and hedge funds.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol.

Receive News & Ratings for Galmed Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Galmed Pharmaceuticals Ltd. (GLMD) Given a $14.00 Price Target at Maxim Group

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) received a $14.00 target price from stock analysts at Maxim Group in a research note issued on Thursday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Maxim Group’s target price would indicate a potential upside of 52.17% from the stock’s previous close.

Several other equities analysts have also commented on GLMD. ValuEngine raised Galmed Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, June 17th. Zacks Investment Research raised Galmed Pharmaceuticals from a “hold” rating to a “buy” rating and set a $8.00 price target on the stock in a research report on Wednesday, August 2nd. Finally, HC Wainwright upped their target price on Galmed Pharmaceuticals from $12.00 to $18.00 and gave the company a “buy” rating in a research report on Tuesday, August 8th.

Shares of Galmed Pharmaceuticals (GLMD) traded up 4.66% on Thursday, reaching $9.20. The company’s stock had a trading volume of 58,840 shares. The stock’s market cap is $112.41 million. Galmed Pharmaceuticals has a 1-year low of $2.78 and a 1-year high of $9.39. The company’s 50 day moving average is $8.24 and its 200-day moving average is $6.41.

Galmed Pharmaceuticals (NASDAQ:GLMD) last released its quarterly earnings results on Monday, July 31st. The biopharmaceutical company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.11. The firm had revenue of $0.27 million for the quarter, compared to analyst estimates of $0.29 million. Galmed Pharmaceuticals had a negative return on equity of 141.13% and a negative net margin of 1,443.98%. On average, equities analysts predict that Galmed Pharmaceuticals will post ($0.94) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Galmed Pharmaceuticals Ltd. (GLMD) Given a $14.00 Price Target at Maxim Group” was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of US & international trademark & copyright laws. The original version of this piece of content can be read at https://www.americanbankingnews.com/2017/10/05/galmed-pharmaceuticals-ltd-glmd-given-a-14-00-price-target-at-maxim-group.html.

A hedge fund recently bought a new stake in Galmed Pharmaceuticals stock. GRT Capital Partners L.L.C. bought a new stake in Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 18,314 shares of the biopharmaceutical company’s stock, valued at approximately $114,000. GRT Capital Partners L.L.C. owned approximately 0.15% of Galmed Pharmaceuticals as of its most recent SEC filing. Institutional investors own 8.32% of the company’s stock.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol.

Receive News & Ratings for Galmed Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Content on this website is not meant to be a recommendation or an offer to buy or sell any security. Click here to read our full disclaimer.